Highlights Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:20:58 2026-04-14 pm EDT			5-day change	1st Jan Change
62.90 ^USD	+1.86%		+3.62%	+36.30%

Mar. 30	Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026.	CI
Mar. 30	Certain Pre-funded warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026.	CI

Highlights

Mar. 23	Vaxcyte Inc Completes Enrollment Of OPUS-1 And OPUS-2 Phase 3 Trials Evaluating VAX-31 For The Prevention Of Invasive Pneumococcal Disease And Pneumonia In Adults	CI
Mar. 18	Vaxcyte, Inc. Publishes Positive Phase 1/2 Adult Data For VAX-31 Pneumococcal Conjugate Vaccine Candidate	CI
Feb. 24	Vaxcyte Q4 Loss Widens	MT
Feb. 24	Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Feb. 11	Vaxcyte, Inc. Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines	CI
Feb. 02	Vaxcyte Closes Public Offering of Shares	MT
Jan. 29	Vaxcyte Launches $500 Million Public Offering	MT
Jan. 22	Vaxcyte, Inc. Advances Adult and Infant Programs for VAX-31, a Potential Best-In-Class, Next-Generation Pneumococcal Conjugate Vaccine	CI
Dec. 08	Vaxcyte, Inc. Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults	CI
Nov. 04	Vaxcyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-16	TSMC Keeps the Dream Alive
25-09-30	Vaxcyte, Inc. to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services	CI
25-09-30	Vaxcyte to Expand Fill-Finish Manufacturing Capacity in US; Shares Up Pre-Bell	MT
25-09-03	Vaxcyte, Inc. Advances VAX-31 Infant Phase 2 Dose- finding Study with First Participants Receiving VAX-31 Optimized Dose	CI
25-08-06	Vaxcyte, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-08	London Calling: Markets Jump
25-05-07	Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-31	Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study	CI
25-02-25	Vaxcyte 2024 Loss Narrows	MT
25-02-25	Earnings Flash (PCVX) Vaxcyte 2024 Loss Per Share $-3.80 vs. FactSet Est Loss of $-4.16	MT
25-02-25	Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-02-05	Vaxcyte, Inc. Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for Prevention of Invasive Pneumococcal Disease in Infants	CI
24-12-03	Vaxcyte, Inc. Initiates Phase 2 Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Infants	CI
24-11-21	Vaxcyte, Inc. Announces Amended and Restated the Original Lease and Enters into Sublease Agreement with Iovance Biotherapeutics, Inc	CI
24-11-12	Vaxcyte, Inc. Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs	CI